Ejiao Act

Bill 117 HR 5203, also known as the Ejiao Act, is a piece of legislation currently being considered by the US Congress. The bill aims to regulate the importation and sale of ejiao, a traditional Chinese medicine made from the gelatin of donkey hides.

The Ejiao Act seeks to address concerns about the ethical treatment of donkeys and the sustainability of the ejiao industry. The bill would require importers and sellers of ejiao to provide documentation proving that the donkey hides used in the production of the medicine were obtained legally and ethically. It would also establish guidelines for the humane treatment of donkeys and set limits on the number of donkeys that can be used for ejiao production.

Supporters of the Ejiao Act argue that it is necessary to protect donkeys from exploitation and ensure the sustainability of the ejiao industry. They believe that regulating the importation and sale of ejiao will help prevent the illegal trafficking of donkey hides and promote responsible sourcing practices. Opponents of the bill, however, argue that it could have negative consequences for the ejiao industry and the traditional Chinese medicine market as a whole. They believe that the regulations proposed in the Ejiao Act could lead to increased costs for producers and consumers, making ejiao less accessible to those who rely on it for its purported health benefits. Overall, the Ejiao Act is a complex piece of legislation that seeks to balance the interests of animal welfare, sustainability, and traditional medicine practices. Its fate in Congress remains uncertain as lawmakers continue to debate the potential impacts of the bill.